Copyright © 2008 Seung-Ah Yoo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003. View at Publisher · View at Google Scholar · View at PubMed
2. A. E. Koch, “Angiogenesis: implications for rheumatoid arthritis,” Arthritis & Rheumatism, vol. 41, no. 6, pp. 951–962, 1998. View at Publisher · View at Google Scholar
3. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at PubMed
4. N. Maruotti, F. P. Cantatore, E. Crivellato, A. Vacca, and D. Ribatti, “Angiogenesis in rheumatoid arthritis,” Histology and Histopathology, vol. 21, no. 4–6, pp. 557–566, 2006.
5. V. Majithia and S. A. Geraci, “Rheumatoid arthritis: diagnosis and management,” The American Journal of Medicine, vol. 120, no. 11, pp. 936–939, 2007. View at Publisher · View at Google Scholar · View at PubMed
6. R. O. Williams, E. Paleolog, and M. Feldmann, “Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases,” Current Opinion in Pharmacology, vol. 7, no. 4, pp. 412–417, 2007. View at Publisher · View at Google Scholar · View at PubMed
7. C. Salliot, M. Dougados, and L. Gossec, “Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials,” Annals of the Rheumatic Diseases, vol. 68, pp. 25–32, 2009. View at Publisher · View at Google Scholar · View at PubMed
8. M. Kowanetz and N. Ferrara, “Vascular endothelial growth factor signaling pathways: therapeutic perspective,” Clinical Cancer Research, vol. 12, no. 17, pp. 5018–5022, 2006. View at Publisher · View at Google Scholar · View at PubMed
9. J. D. Gorman, “Smoking and rheumatoid arthritis: another reason to just say no,” Arthritis & Rheumatism, vol. 54, no. 1, pp. 10–13, 2006. View at Publisher · View at Google Scholar · View at PubMed
10. M. Raidl, B. Sibbing, J. Strauch, et al., “Impaired TNF$\alpha$-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation—effect of dexamethasone,” Cell Biochemistry and Biophysics, vol. 49, no. 2, pp. 98–110, 2007. View at Publisher · View at Google Scholar
11. N. Rovina, A. Papapetropoulos, A. Kollintza, et al., “Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?,” Respiratory Research, vol. 8, article 53, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at PubMed
12. I. Edirisinghe, S.-R. Yang, H. Yao, et al., “VEGFR-2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction,” The FASEB Journal, vol. 22, no. 7, pp. 2297–2310, 2008. View at Publisher · View at Google Scholar · View at PubMed
13. S.-S. Lee, Y.-S. Joo, W.-U. Kim, et al., “Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 19, no. 3, pp. 321–324, 2001.
14. S.-A. Yoo, D.-G. Bae, J.-W. Ryoo, et al., “Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-$\alpha$ and IL-6 by human monocytes,” The Journal of Immunology, vol. 174, no. 9, pp. 5846–5855, 2005.
15. C.-S. Cho, M.-L. Cho, S.-Y. Min, et al., “CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor,” The Journal of Immunology, vol. 164, no. 10, pp. 5055–5061, 2000.
16. S. Ryu, J. H. Lee, and S. I. Kim, “IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes,” Clinical Rheumatology, vol. 25, no. 1, pp. 16–20, 2006. View at Publisher · View at Google Scholar · View at PubMed
17. M.-L. Cho, Y. O. Jung, Y.-M. Moon, et al., “Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways,” Immunology Letters, vol. 103, no. 2, pp. 159–166, 2006. View at Publisher · View at Google Scholar · View at PubMed
18. A. W. Mould, I. D. Tonks, M. M. Cahill, et al., “Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis,” Arthritis & Rheumatism, vol. 48, no. 9, pp. 2660–2669, 2003. View at Publisher · View at Google Scholar · View at PubMed
19. H. Oura, J. Bertoncini, P. Velasco, L. F. Brown, P. Carmeliet, and M. Detmar, “A critical role of placental growth factor in the induction of inflammation and edema formation,” Blood, vol. 101, no. 2, pp. 560–567, 2003. View at Publisher · View at Google Scholar · View at PubMed
20. T. Marumo, V. B. Schini-Kerth, and R. Busse, “Vascular endothelial growth factor activates nuclear factor-$\kappa$B and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells,” Diabetes, vol. 48, no. 5, pp. 1131–1137, 1999. View at Publisher · View at Google Scholar
21. T.-H. Lee, H. Avraham, S.-H. Lee, and S. Avraham, “Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 12, pp. 10445–10451, 2002. View at Publisher · View at Google Scholar · View at PubMed
22. G. S. Firestein, “Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?,” Arthritis & Rheumatism, vol. 39, no. 11, pp. 1781–1790, 1996. View at Publisher · View at Google Scholar
23. W.-U. Kim, S. S. Kang, S.-A. Yoo, et al., “Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation,” The Journal of Immunology, vol. 177, no. 8, pp. 5727–5735, 2006.
24. A. Luttun, M. Tjwa, and P. Carmeliet, “Placental growth factor (PIGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders,” Annals of the New York Academy of Sciences, vol. 979, pp. 80–93, 2002.
25. M. Autiero, A. Luttun, M. Tjwa, and P. Carmeliet, “Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders,” Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1356–1370, 2003. View at Publisher · View at Google Scholar
26. S. Soker, S. Takashima, H. Q. Miao, G. Neufeld, and M. Klagsbrun, “Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor,” Cell, vol. 92, no. 6, pp. 735–745, 1998. View at Publisher · View at Google Scholar
27. R. Mamluk, Z. Gechtman, M. E. Kutcher, N. Gasiunas, J. Gallagher, and M. Klagsbrun, “Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain,” The Journal of Biological Chemistry, vol. 277, no. 27, pp. 24818–24825, 2002. View at Publisher · View at Google Scholar · View at PubMed
28. Z. He and M. Tessier-Lavigne, “Neuropilin is a receptor for the axonal chemorepellent semaphorin III,” Cell, vol. 90, no. 4, pp. 739–751, 1997. View at Publisher · View at Google Scholar
29. R. E. Bachelder, A. Crago, J. Chung, et al., “Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells,” Cancer Research, vol. 61, no. 15, pp. 5736–5740, 2001.
30. M. Ikeda, Y. Hosoda, S. Hirose, Y. Okada, and E. Ikeda, “Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis,” The Journal of Pathology, vol. 191, no. 4, pp. 426–433, 2000. View at Publisher · View at Google Scholar
31. H. S. Kim, S.-A. Yoo, H. J. Yoon, S. H. Park, C. S. Cho, and W.-U. Kim, “Role of placental growth factor and its receptor Flt-1 in rheumatoid inflammation,” Arthritis & Rheumatism. In press.
32. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Publisher · View at Google Scholar · View at PubMed
33. J. C. Yang, L. Haworth, R. M. Sherry, et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” The New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at PubMed
34. A. Sandler, R. Gray, M. C. Perry, et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” The New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at PubMed
35. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham, Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at PubMed
36. A. Kiselyov, K. V. Balakin, and S. E. Tkachenko, “VEGF/VEGFR signalling as a target for inhibiting angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 1, pp. 83–107, 2007. View at Publisher · View at Google Scholar · View at PubMed
37. H. Sone, Y. Kawakami, M. Sakauchi, et al., “Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice,” Biochemical and Biophysical Research Communications, vol. 281, no. 2, pp. 562–568, 2001. View at Publisher · View at Google Scholar · View at PubMed
38. J. Miotla, R. Maciewicz, J. Kendrew, M. Feldmann, and E. Paleolog, “Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis,” Laboratory Investigation, vol. 80, no. 8, pp. 1195–1205, 2000. View at Publisher · View at Google Scholar
39. M. De Bandt, M. H. Ben Mahdi, V. Ollivier, et al., “Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis,” The Journal of Immunology, vol. 171, no. 9, pp. 4853–4859, 2003.
40. M. Murakami, S. Iwai, S. Hiratsuka, et al., “Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages,” Blood, vol. 108, no. 6, pp. 1849–1856, 2006. View at Publisher · View at Google Scholar · View at PubMed
41. M.-L. Cho, C.-S. Cho, S.-Y. Min, et al., “Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts,” Arthritis & Rheumatism, vol. 46, no. 5, pp. 1202–1209, 2002. View at Publisher · View at Google Scholar · View at PubMed
42. I. Macías, S. García-Pérez, M. Ruiz-Tudela, F. Medina, N. Chozas, and J. A. Girón-González, “Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-$\alpha$ blockade in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 32, no. 11, pp. 2102–2108, 2005.
43. D.-G. Bae, T.-D. Kim, G. Li, W.-H. Yoon, and C.-B. Chae, “Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis,” Clinical Cancer Research, vol. 11, no. 7, pp. 2651–2661, 2005. View at Publisher · View at Google Scholar · View at PubMed
44. J. DiSalvo, M. L. Bayne, G. Conn, et al., “Purification and characterization of a naturally occurring vascular endothelial growth factor. Placenta growth factor heterodimer,” The Journal of Biological Chemistry, vol. 270, no. 13, pp. 7717–7723, 1995. View at Publisher · View at Google Scholar
45. M. Clauss, H. Weich, G. Breier, et al., “The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis,” The Journal of Biological Chemistry, vol. 271, no. 30, pp. 17629–17634, 1996. View at Publisher · View at Google Scholar
46. S. K. Selvaraj, R. K. Giri, N. Perelman, C. Johnson, P. Malik, and V. K. Kalra, “Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor,” Blood, vol. 102, no. 4, pp. 1515–1524, 2003. View at Publisher · View at Google Scholar · View at PubMed
47. M. J. Bottomley, N. J. A. Webb, C. J. Watson, et al., “Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid,” Clinical & Experimental Immunology, vol. 119, no. 1, pp. 182–188, 2000. View at Publisher · View at Google Scholar
48. C. Fischer, B. Jonckx, M. Mazzone, et al., “Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels,” Cell, vol. 131, no. 3, pp. 463–475, 2007. View at Publisher · View at Google Scholar · View at PubMed
49. A. P. Taylor and D. M. Goldenberg, “Role of placenta growth factor in malignancy and evidence that an antagonistic PIGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts,” Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 524–531, 2007. View at Publisher · View at Google Scholar · View at PubMed